The pharmaceutical company said its ceralasertib combination didn’t meet the primary goal of a late-stage clinical trial for ...

AstraZeneca PLC (NASDAQ: AZN) announced on Monday that its Phase III LATIFY clinical trial evaluating ceralasertib in ...

AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...

Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...

DNA-PK inhibitor compounds have potential in solid tumors and blood cancers. The AstraZeneca subsidiary, KuDOS Pharmaceuticals, exercised its option to license exclusive rights to a DNA-dependent ...

-- Niowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca -- 10-year supply agreement will help advance new radioconjugate therapies capable of ...

Drugs that interfere with a way tumors repair damage to their DNA have become valuable tools for treating certain cancers. Some big pharmaceutical companies are developing drugs that improve on this ...

Nov 1 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday it would invest $245 million in French biotechnology company Cellectis (ALCLS.PA), opens new tab in a deal aimed at speeding up ...

Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) is indicated for the treatment ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization ...